Osteoporosis News and Research

Latest Osteoporosis News and Research

Stryker Interventional Spine announces the U.S. launch of VertaPlex HV bone cement for VCFs

Stryker Interventional Spine today announced the U.S. launch of VertaPlex® HV. VertaPlex HV is a high viscosity bone cement for use in treating vertebral compression fractures.

From Stryker 2 Mar 2010

Synexus recruits 87% of agreed number of patients in major osteoporosis study within deadline

Following the recent announcement from Manchester-based Synexus that they had randomised 2,700 patients in just ten months for an osteoporosis study, the company has once again demonstrated that it is possible to recruit the agreed number of patients within the study deadline by recruiting 87% of patients to another study for the same therapeutic area.

From AES - Accelerated Enrollment Solutions 1 Mar 2010

UAMS researchers identify age-related mechanism as primary cause of osteoporosis

Marking a shift in decades of thought on the cause of osteoporosis, researchers at the University of Arkansas for Medical Sciences have identified an age-related mechanism - not a decrease of the hormone estrogen - as the primary culprit.

27 Feb 2010

$Fragility fractures: 'Own the Bone' program for enhancing prevention and treatment$

Fragility fractures: 'Own the Bone' program for enhancing prevention and treatment

As many as half of all women and a quarter of men over the age of 50 can expect to sustain a fractured bone related to osteoporosis or low bone density. To enhance prevention and treatment of these fragility fractures, NewYork-Presbyterian Hospital/Columbia University Medical Center has implemented an innovative program called Own the Bone™ developed by the American Orthopaedic Association.

26 Feb 2010

RF Kyphoplasty procedure using StabiliT Vertebral Augmentation System: DFine treats over 2000 patients

DFine, Inc., a developer of minimally invasive solutions for treating vertebral compression fractures, announced today that over 2,000 patients with over 3000 fractures have been treated globally with the RF Kyphoplasty procedure using the StabiliT® Vertebral Augmentation System.

26 Feb 2010

NIH panel proposes multiple management strategies for lactose intolerant individuals

Lactose intolerance is a real and important clinical syndrome, but quantifying its public health burden is challenging. An NIH Consensus Development panel was convened this week to assess the available evidence on lactose intolerance and health across the age spectrum and across racial and ethnic groups.

25 Feb 2010

Low doses of lasofoxifene reduce all common problems in postmenopausal women: Study

Low doses of the medication lasofoxifene can reduce the risk of vertebral and non-vertebral fractures, ER-positive breast cancer, coronary heart disease and stroke in postmenopausal women with osteoporosis. That's the finding of a new study in the latest issue of the New England Journal of Medicine.

25 Feb 2010

More research needed for osteoporosis treatments

Dr. Angelo Malamis says that 90 percent of his patients who have undergone a treatment called balloon kyphoplasty for vertebral fractures report significant reductions in pain and disability.

23 Feb 2010

Ritter Pharmaceuticals to discuss lactose intolerance and associated health risks at NIH Conference

Ritter Pharmaceuticals, a company dedicated to helping individuals live a healthier and happier life style through improved digestion, announced today that it will join the leading lactose intolerance experts around the country at the NIH Consensus Development Conference for Lactose Intolerance and Health in Bethesda, Maryland from February 22-24.

22 Feb 2010

Amgen's Prolia Complete Response submission: FDA classifies and sets PDUFA date

Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has evaluated the content of the Company's Complete Response submission for Prolia™ (denosumab) in the treatment of postmenopausal osteoporosis and classified it as a Class 2 resubmission. With the Class 2 designation, the FDA set a corresponding Prescription Drug User Fee Act (PDUFA) action date of July 25, 2010.

20 Feb 2010

Most important osteoporosis meeting of 2010: More than 850 abstracts received

More than 850 abstracts have been received - guaranteeing broad global attendance at the year's most noteworthy platform for osteoporosis research. Don't miss the most important osteoporosis meeting of 2010, to be held in the center of Florence, Italy from May 5 to 8, 2010.

19 Feb 2010

Vertebroplasty effective in treatment of VCFs

The results of a study of more than 4500 patients from six Italian EVEREST (European Vertebroplasty Research Team) Centers (Dr. G.C. Anselmetti-Candiolo Torino, Dr. G. Bonaldi-Bergamo, Dr. P. Carpeggiani-Pisa, Dr. S. Masala-Roma, Dr. M. Muto-Napoli,) confirms the effectiveness of vertebroplasty in treating vertebral compression fractures (VCFs), finding that the procedure provides significant and sustained pain relief.

18 Feb 2010

Norwegian government task force suggests formation of single company to commercialise biomaterial assets

Having studied the ethical, judicial and political arguments, the Norwegian government task force has suggested that a single nationwide company should be formed to commercialise biomaterials assets from the country’s various sources. The task force has also recommended HUNT Biosciences be a model for the national company.

18 Feb 2010

Single test is not enough for making accurate diagnosis of disc herniation

While lower back pain ranks as a common cause of disability in the United States, determining what causes a person's back pain is often challenging. A new Cochrane review on diagnosing back pain finds that no single diagnostic test is good at discriminating between patients who have a herniated disc and patients who do not, according to lead author Danielle van der Windt.

18 Feb 2010

HealthYes! expands life-saving mobile screening services to Oklahoma

HealthYes!®, a leading preventive medical screening company, is bringing its life-saving mobile screening services to Oklahoma. Leveraging the most medically advanced, state-of-the-art equipment and techniques in the industry, HealthYes! screens its clients for life-threatening medical conditions and diseases including: heart disease, stroke, abdominal aortic aneurysm, peripheral artery disease, diabetes and liver disease along with osteoporosis.

18 Feb 2010

Postmenopausal women undergoing combination hormone therapy at increased risk of heart disease: WHI confirms

New analyses from the Women's Health Initiative (WHI) confirm that combination hormone therapy increases the risk of heart disease in healthy postmenopausal women. Researchers report a trend toward an increased risk of heart disease during the first two years of hormone therapy among women who began therapy within 10 years of menopause, and a more marked elevation of risk among women who began hormone therapy more than 10 years after menopause. Analyses indicate that overall a woman's risk of heart disease more than doubles within the first two years of taking combination HT.

17 Feb 2010

Osseon Therapeutics completes first Osseoplasty procedures in Europe

Osseon Therapeutics Inc. today announced it has completed its first Osseoplasty™ procedures in Europe. The procedures were performed in Milan, Italy.

17 Feb 2010

Synexus takes just ten months to carry out 52,000 DEXA scans

It took clinical trial experts Synexus, just ten months to carry out 52,000 DEXA scans and randomise over 2,700 patients across twelve of their UK, European and African dedicated research centres.

From AES - Accelerated Enrollment Solutions 15 Feb 2010

Pacific Biomarkers announces second-quarter fiscal 2010 results

Pacific Biomarkers, Inc., a leading provider of specialized biomarker and contract research services, today announced its operating results for the second quarter and first half of FY2010.

12 Feb 2010

Oral hygiene: Insights

Oral health is often the window to your overall health. Evidence has supported the link between poor oral health and such conditions as stroke, premature birth and diabetes. Other conditions, such as HIV/AIDS and osteoporosis may show preliminary signs in your mouth, before other areas of the body are affected. Also, some of your daily activities or habits can affect your oral health. Therefore, it's wise to pay attention to your teeth and gums.

11 Feb 2010

Osteoporosis News and Research

Latest Osteoporosis News and Research

Stryker Interventional Spine announces the U.S. launch of VertaPlex HV bone cement for VCFs

Synexus recruits 87% of agreed number of patients in major osteoporosis study within deadline

UAMS researchers identify age-related mechanism as primary cause of osteoporosis

Fragility fractures: 'Own the Bone' program for enhancing prevention and treatment

RF Kyphoplasty procedure using StabiliT Vertebral Augmentation System: DFine treats over 2000 patients

NIH panel proposes multiple management strategies for lactose intolerant individuals

Low doses of lasofoxifene reduce all common problems in postmenopausal women: Study

More research needed for osteoporosis treatments

Ritter Pharmaceuticals to discuss lactose intolerance and associated health risks at NIH Conference

Amgen's Prolia Complete Response submission: FDA classifies and sets PDUFA date

Most important osteoporosis meeting of 2010: More than 850 abstracts received

Vertebroplasty effective in treatment of VCFs

Norwegian government task force suggests formation of single company to commercialise biomaterial assets

Single test is not enough for making accurate diagnosis of disc herniation

HealthYes! expands life-saving mobile screening services to Oklahoma

Postmenopausal women undergoing combination hormone therapy at increased risk of heart disease: WHI confirms

Osseon Therapeutics completes first Osseoplasty procedures in Europe

Synexus takes just ten months to carry out 52,000 DEXA scans

Pacific Biomarkers announces second-quarter fiscal 2010 results

Oral hygiene: Insights

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Osteoporosis News and Research

Latest Osteoporosis News and Research

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in